ERS Genomics & Transomic Technologies enter into CRISPR/Cas9 Licensing Agreement

License allows Transomic Technologies to develop and commercialize products using CRISPR/Cas9.

Dublin, Ireland and Huntsville, AL, USA,  August 3, 2023:  ERS Genomics Limited (‘ERS’) is pleased to announce a new license agreement with Transomic Technologies (‘Transomic,’). This is a non-exclusive licensing agreement granting Transomic access to the foundational ERS CRISPR/Cas9 patent portfolio.

Dr. Emmanuelle Charpentier, founder of ERS Genomics, received the 2020 Nobel Prize for the discovery of CRISPR/Cas9. As a direct outcome, the ERS patent portfolio stands as the definitive collection of proprietary rights to this gene editing technology.

Founded in 2012, Transomic’s mission is to equip life science researchers with cutting-edge gene modulation tools derived from the forefront of biotechnology advancements. Specializing in molecular cloning, their portfolio of products and services revolves around vector-based solutions.

Commenting on the deal with ERS, Blake Simmons, CEO, Transomic Technologies  had the following statement: “Transomic recognizes the extremely valuable role that gene editing technology plays in life science research and drug discovery.  We are very excited to be able to continue to expand our CRISPR/Cas9 research tools business by licensing this important patent portfolio from ERS genomics.

Eric Rhodes, CEO, ERS Genomics was equally enthusiastic about the new agreement: ‘Transomic has established an impressive reputation for providing scientists with accessible and innovative solutions. This works well with our fundamental mission of driving scientific progress through expanding access across our industry to the potential of CRISPR/Cas9.’

Financial details of the agreement are not being disclosed.